129 results on '"Alpay N"'
Search Results
2. Insulin resistance and coronary flow velocity reserve in patients with autosomal dominant polycystic kidney disease
- Author
-
Turkmen, K., Tufan, F., Alpay, N., Kaskcoglu, E., Oflaz, H., Ecder, S. A., and Ecder, T.
- Published
- 2012
- Full Text
- View/download PDF
3. Veränderung der Lungenfunktion während Platin-haltiger Chemotherapie bei Lungenkarzinom
- Author
-
Götschke, J, additional, von Wachter, C, additional, Sellmer, L, additional, Mertsch, P, additional, Kauffmann-Guerrero, D, additional, Syunyaeva, Z, additional, Alpay, N, additional, and Tufman, A, additional
- Published
- 2020
- Full Text
- View/download PDF
4. Effects of exercise on periodontal parameters in obese women
- Author
-
Guzeldemir-Akcakanat, E, primary, Alkan, B, additional, Odabas-Ozgur, B, additional, Ozgur, T, additional, Demirdizen-Taskiran, A, additional, Kir, HM, additional, Alpay, N, additional, and Cayci-Akkan, E, additional
- Published
- 2020
- Full Text
- View/download PDF
5. Electrostatic hot spot on DNA-binding domains mediates phosphate desolvation and the pre-organization of specificity determinant side chains
- Author
-
Temiz, Alpay N., Benos, Panayiotis V., and Camacho, Carlos J.
- Published
- 2010
- Full Text
- View/download PDF
6. A case of paroxysmal nocturnal hemoglobinuria presenting with intra-abdominal bleeding due to splenic rupture, developing renal infarct
- Author
-
UZUN, S., ALPAY, N., OZTURK, G. B., SAKA, B., YENEREL, M., ERTEN, N., KARAN, M. A., and TAŞCIOGLU, C.
- Published
- 2008
7. Conformational Changes in HIV-1 Reverse Transcriptase Induced by Nonnucleoside Reverse Transcriptase Inhibitor Binding
- Author
-
Sluis-Cremer, Nicolas, Temiz, Alpay N., and Bahar, Ivet
- Published
- 2004
8. Introducing the non-B DNA Motif Search Tool (nBMST)
- Author
-
Cer, Regina Z, Bruce, Kevin H, Donohue, Duncan E, Temiz, Alpay N, Bacolla, Albino, Mudunuri, Uma S, Yi, Ming, Volfovsky, Natalia, Luke, Brian T, Collins, Jack R, and Stephens, Robert M
- Published
- 2011
- Full Text
- View/download PDF
9. Effects of Exercise on Periodontal Parameters in Obese Women.
- Author
-
Alkan, B., Guzeldemir-Akcakanat, E., Odabas-Ozgur, B., Ozgur, T., Demirdizen-Taskiran, A., Kir, H. M., Alpay, N., and Cayci-Akkan, E.
- Published
- 2020
- Full Text
- View/download PDF
10. Dentists knowledge of lipid treatment of local anaesthetic systemic toxicity
- Author
-
Oksuz, G, primary, Urfalioglu, A, additional, Sekmen, T, additional, Akkececi, N, additional, Alpay, N, additional, and Bilal, B, additional
- Published
- 2018
- Full Text
- View/download PDF
11. AB0868 Is it appropriate to discontinue colchicine therapy in gout patients in remission?
- Author
-
Özdem, Y İnan, primary, Alpay, N Kanıtez, additional, Çelik, S, additional, Yılmaz, S Öner, additional, and Bes, C, additional
- Published
- 2017
- Full Text
- View/download PDF
12. Conversion from Calcineurin Inhibitors to Everolimus Resulted in Decrease of Serum TGF-beta and Urinary NGAL in Renal Transplant Recipients
- Author
-
Alpay, N., Özkök, A., Calışkan, Y., Akagün, Tülin, Çınar, S., Deniz, G., Yıldız, A., Fakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı, and Akagün, Tülin
- Abstract
13th American Transplant Congress (ATC) -- MAY 18-22, 2013 -- Seattle, WA Adin-Cinar, Suzan/0000-0002-8330-7010; WOS: 000318240301956 Background and Aim Calcineurin inhibitor (CNI) treatment has been implicated for chronic allograft dysfunction in renal transplant recipients. We aimed to investigate the effects of switch from CNI to Everolimus treatment on serum/urinary markers of fibrosis (TGF-beta), inflammation, glomerular and tubular injury.
- Published
- 2013
13. P.2.h.007 Effects of antidepressants on temperament, character and defense mechanisms in major depression
- Author
-
Tabakci, A.S, primary, Aksoy, U.M, additional, Erkiran, M., additional, Tuna, O., additional, Buket Tomruk, N., additional, and Alpay, N., additional
- Published
- 2015
- Full Text
- View/download PDF
14. P.1.c.014 The effect of predominant polarity on clinical findings and the course of bipolar disorder
- Author
-
Coğalmş, F.B., primary, Tomruk, N.B., additional, Tabakçi, A.S., additional, and Alpay, N., additional
- Published
- 2015
- Full Text
- View/download PDF
15. Abstract B01: Mechanisms of treatment resistance following Ras targeted therapy in acute myeloid leukemia.
- Author
-
Eckfeldt, Craig E., primary, Lee, Robin DW, additional, Pomeroy, Emily J., additional, Temiz, Alpay N., additional, Rathe, Susan K., additional, Ma, Jing, additional, Gruber, Tanja A., additional, Diaz-Flores, Ernesto, additional, Downing, James R., additional, Shannon, Kevin M., additional, and Largaespada, David A., additional
- Published
- 2015
- Full Text
- View/download PDF
16. Antagonism of Tumoral Prolactin Receptor Promotes Autophagy-Related Cell Death
- Author
-
Wen, Y, Zand, B, Ozpolat, B, Szczepanski, MJ, Lu, C, Yuca, E, Carroll, AR, Alpay, N, Bartholomeusz, C, Tekedereli, I, Kang, Y, Rupaimoole, R, Pecot, CV, Dalton, HJ, Hernandez, A, Lokshin, A, Lutgendorf, SK, Liu, J, Hittelman, WN, Chen, WY, Lopez-Berestein, G, Szajnik, M, Ueno, NT, Coleman, RL, Sood, AK, Wen, Y, Zand, B, Ozpolat, B, Szczepanski, MJ, Lu, C, Yuca, E, Carroll, AR, Alpay, N, Bartholomeusz, C, Tekedereli, I, Kang, Y, Rupaimoole, R, Pecot, CV, Dalton, HJ, Hernandez, A, Lokshin, A, Lutgendorf, SK, Liu, J, Hittelman, WN, Chen, WY, Lopez-Berestein, G, Szajnik, M, Ueno, NT, Coleman, RL, and Sood, AK
- Abstract
Therapeutic upregulation of macroautophagy in cancer cells provides an alternative mechanism forcell death. Prolactin (PRL) and its receptor (PRLR) are considered attractive therapeutic targets because of their roles as growth factors in tumor growth and progression. We utilized G129R, an antagonist peptide of PRL, to block activity of the tumoral PRL/PRLR axis, which resulted in inhibition of tumor growth in orthotopic models of human ovarian cancer. Prolonged treatment with G129R induced the accumulation of redundant autolysosomes in 3D cancer spheroids, leading to a type II programmed cell death. This inducible autophagy was a noncanonical beclin-1-independent pathway and was sustained by an astrocytic phosphoprotein (PEA-15) and protein kinase C zeta interactome. Lower levels of tumoral PRL/PRLR inclinical samples were associated with longer patient survival. Our findings provide an understanding of the mechanisms of tumor growth inhibition through targeting PRL/PRLR and may have clinical implications. © 2014 The Authors.
- Published
- 2014
17. Unintentional endosulfan poisoning
- Author
-
Satar, S., Sebe, A., Alpay, N. R., Gumusay, U., Ozlem Guneysel, and Çukurova Üniversitesi
- Subjects
Hemodialysis ,Poisoning ,Emergency ,Status epilepticus ,Endosulfan - Abstract
PubMedID: 19507667 Endosulfan is an organochloride insecticide, widely used in insect control. It is responsible for many severe intoxication and several deaths. We present a case series of endosulfan poisoning, admitted to our emergency department with different clinical courses. Two patients presented with status epilepticus and were successfully treated with thiopental sodium to control seizures. One patient required also hemodialysis. All patients were discharged following a complete recovery of their health. Endosulfan is a highly toxic insecticide that produces tonic-clonic convulsions, headache, dizziness and ataxia. It can cause also life threatening metabolic disturbances. Treatment is symptomatic and supportive.
- Published
- 2009
18. Abstract B01: Mechanisms of treatment resistance following Ras targeted therapy in acute myeloid leukemia
- Author
-
Susan K. Rathe, James R. Downing, David A. Largaespada, Alpay N. Temiz, Ernesto Diaz-Flores, Craig E. Eckfeldt, Jing Ma, Tanja A. Gruber, Emily J. Pomeroy, Kevin Shannon, and Robin Dw Lee
- Subjects
Neuroblastoma RAS viral oncogene homolog ,Cancer Research ,Oncogene ,medicine.medical_treatment ,Myeloid leukemia ,Cancer ,Biology ,medicine.disease ,Bioinformatics ,Targeted therapy ,Fusion gene ,Leukemia ,Oncology ,hemic and lymphatic diseases ,medicine ,Cancer research ,MYB ,neoplasms - Abstract
Ras proto-oncogenes and numerous effectors of Ras signaling are recurrently mutated in acute myeloid leukemia (AML). While Ras represents an attractive therapeutic target, attempts at targeting oncogenic Ras directly have not been successful. To evaluate potential mechanisms of resistance to Ras targeted treatment in AML, our group leveraged a robust genetically-engineered mouse model in which AML is driven by expression of a tetracycline-repressible, constitutively active NRAS oncogene, tre-NRAS(V12), and a Mll-AF9 “knock-in” leukemogenic fusion gene (tre-NRAS(V12) & Mll-AF9 or tNM AML). The leukemia cells in this model are “addicted” to NRAS(V12), and mimicking Ras targeted treatment by doxycycline (Dox)-mediated suppression of the tre-NRAS(V12) oncogene expression results in rapid eradication of AML cells in vitro and in vivo. Furthermore, prolonged suppression of NRAS(V12) expression in NRAS(V12)-dependent (NRD) AML leads to the spontaneous development of NRAS(V12)-independent (NRI), “relapsed/refractory”, AML in about half of Dox treated mice. To elucidate the mechanism(s) that lead to the development of “relapsed/refractory” NRI AML following suppression of NRAS(V12) we performed transcriptome-wide next generation RNA-sequencing and comprehensive flow cytometric analysis of cancer signaling pathways comparing the parental NRD AML and two NRI AMLs. We confirmed that the NRAS(V12) oncogene is not aberrantly re-expressed. Furthermore, endogenous Ras gene expression is not up-regulated, and there is no evidence of reactivation of canonical Ras effector signaling pathways in either of the NRI AMLs by phospho-flow cytometry. Our preliminary analysis of cancer signaling pathways and transcriptome-wide RNA sequencing have identified candidate mediators of NRAS(V12)-independent AML growth and survival including the Myb proto-oncogene and anti-apoptotic Bcl2 that are enriched in both NRI AMLs relative to NRD AML at both the transcript and protein level. Furthermore, Myc protein is enriched in both NRI AMLs compared to NRD AML. We are currently performing a more comprehensive analysis of our next-generation RNA sequencing data to refine our list of candidate genes, and investigating the potential functional roles of Bcl2, Myb, and Myc in the development of NRI AML. In our initial functional studies, inhibition of Bcl2 activity suppresses NRI AML leukemic colony formation in vitro, and we are currently evaluating the ability of enforced expression of Bcl2, Myb, or Myc in NRD AML cells to render them NRAS(V12)-independent. To further investigate the translational potential of our findings, we are also evaluating the anti-leukemic effect of clinically relevant inhibitors of Bcl2 with inhibitors of canonical Ras effector pathways (RAF-MEK-ERK and PI3K-AKT-mTOR) in preclinical AML models. In this way we hope to gain a better understanding of mechanisms of treatment resistance to Ras targeted therapies, and thereby provide a foundation for the rational development of novel targeted treatment approaches for AML. Citation Format: Craig E. Eckfeldt, Robin DW Lee, Emily J. Pomeroy, Alpay N. Temiz, Susan K. Rathe, Jing Ma, Tanja A. Gruber, Ernesto Diaz-Flores, James R. Downing, Kevin M. Shannon, David A. Largaespada. Mechanisms of treatment resistance following Ras targeted therapy in acute myeloid leukemia. [abstract]. In: Proceedings of the AACR Special Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies; Sep 20-23, 2014; Philadelphia, PA. Philadelphia (PA): AACR; Clin Cancer Res 2015;21(17 Suppl):Abstract nr B01.
- Published
- 2015
19. The role of Chlamydophila pneumoniae in the etiopathogenesis of schizophrenia and brain-derived neurotrophic factor (BDNF), neurotrophins like neurotrophin 3 (NT3) levels: A worldwide retrospective study
- Author
-
Kalayci, F., primary, Balcioglu, I., additional, Ozdemir, A., additional, Yuksel, P., additional, Alpay, N., additional, Ergin, S., additional, Kuskucu, M., additional, Kurt, A., additional, Aksoy Poyraz, C., additional, Bahar Tokman, H., additional, and Kocazeybek, B., additional
- Published
- 2014
- Full Text
- View/download PDF
20. P01-020 – Starting time of inflammatory attacks in patients
- Author
-
Berktaş, F, primary, Alpay, N, additional, Toz, B, additional, Bakkaloğlu, OK, additional, Erer, B, additional, and Gül, A, additional
- Published
- 2013
- Full Text
- View/download PDF
21. AB0510 The relationship between nailfold capillaroscopic assessment and telangiectasia score with severity of peripheral vascular involvement in systemic sclerosis
- Author
-
Yalcinkaya, Y., primary, Pehlivan, O., additional, Alpay, N., additional, Omma, A., additional, Erer, B., additional, Kamali, S., additional, Ocal, L., additional, and Inanc, M., additional
- Published
- 2013
- Full Text
- View/download PDF
22. AB0437 Predictivity of serum biomarkers for disease activity in a prospectively followed-up takayasu arteritis cohort: is serum amyloid a protein better than conventional acute phase markers?
- Author
-
Omma, A., primary, Erer, B., additional, Alpay, N., additional, Gurel Polat, N., additional, Gul, A., additional, Inanc, M., additional, and Kamali, S., additional
- Published
- 2013
- Full Text
- View/download PDF
23. Transplantation - clinical studies II
- Author
-
Marques, I. B., primary, Silva, R. d. M., additional, Moraes, C. E., additional, Azevedo, L. S., additional, Nahas, W. C., additional, David-Neto, E., additional, Furmanczyk-Zawiska, A., additional, Baczkowska, T., additional, Chmura, A., additional, Szmidt, J., additional, Durlik, M., additional, Joslin, J., additional, Blaker, P., additional, White, B., additional, Marinaki, A., additional, Sanderson, J., additional, Goldsmith, D. J., additional, Medani, S., additional, Traynor, C., additional, Mohan, P., additional, Little, D., additional, Conlon, P., additional, Molina, M., additional, Gonzalez, E., additional, Gutierrez, E., additional, Sevillano, A., additional, Polanco, N., additional, Morales, E., additional, Hernandez, A., additional, Praga, M., additional, Morales, J. M., additional, Andres, A., additional, Park, S. J., additional, Kim, T. H., additional, Kim, Y. W., additional, Kim, Y. H., additional, Kang, S. W., additional, Kujawa-Szewieczek, A., additional, Szotowska, M., additional, Kuczera, P., additional, Chudek, J., additional, Wiecek, A., additional, Kolonko, A., additional, Mahrova, A., additional, Svagrova, K., additional, Bunc, V., additional, Stollova, M., additional, Teplan, V., additional, Hundt, F., additional, van Heteren, P., additional, Woitas, R., additional, Cavallo, M. C., additional, Sepe, V., additional, Conte, F., additional, Albrizio, P., additional, Bottazzi, A., additional, Geraci, P. M., additional, Alpay, N., additional, Gumber, M. R., additional, Kute, V. B., additional, Vanikar, A. V., additional, Patel, H. V., additional, Shah, P. R., additional, Engineer, D. P., additional, Trivedi, H. L., additional, Golebiewska, J. E., additional, Debska-Slizien, A., additional, Rutkowski, B., additional, Matias, P., additional, Martins, A. R., additional, Raposo, L., additional, Jorge, C., additional, Weigert, A., additional, Birne, R., additional, Bruges, M., additional, Adragao, T., additional, Almeida, M., additional, Mendes, M., additional, Machado, D., additional, Masin-Spasovska, J., additional, Dohcev, S., additional, Stankov, O., additional, Stavridis, S., additional, Saidi, S., additional, Dejanova, B., additional, Rambabova-Busletic, I., additional, Dejanov, P., additional, Spasovski, G., additional, Nho, K. W., additional, Han, D. J., additional, Park, S.-K., additional, Kim, S. B., additional, Fenoglio, R., additional, Lazzarich, E. E., additional, Cagna, D., additional, Cena, T., additional, Conti, N., additional, Quaglia, M., additional, Radin, E., additional, Izzo, C., additional, Stratta, P., additional, Oh, I. H., additional, Park, J.-S., additional, Lee, C. H., additional, Kang, C. M., additional, Kim, G.-H., additional, Leone, F., additional, Lofaro, D., additional, Gigliotti, P., additional, Lupinacci, S., additional, Toteda, P., additional, Vizza, D., additional, Perri, A., additional, Papalia, T., additional, Bonofiglio, R., additional, di Loreto, P., additional, de Silvestro, L., additional, Montanaro, D., additional, Martino, F., additional, Sandrini, S., additional, Minetti, E., additional, Cabiddu, G., additional, Yildirim, T., additional, Yilmaz, R., additional, Turkmen, E., additional, Abudalal, A., additional, Altindal, M., additional, Ertoy-Baydar, D., additional, Erdem, Y., additional, Panuccio, V., additional, Tripepi, R., additional, Parlongo, G., additional, Versace, M. C., additional, Politi, R., additional, Zoccali, C., additional, Mallamaci, F., additional, Porrini, E., additional, Silva, I., additional, Diaz, J., additional, Ibernon, M., additional, Moreso, F., additional, Benitez, R., additional, Delgado Mallen, P., additional, Osorio, J., additional, Lauzurica, R., additional, Torres, A., additional, Ersoy, A., additional, Koca, N., additional, Gullu Koca, T., additional, Kirhan, E., additional, Sarandol, E., additional, Ersoy, C., additional, Dirican, M., additional, Milne, J., additional, Suter, V., additional, Mikhail, A., additional, Akalin, H., additional, Dizdar, O., additional, Pascual, J., additional, Torio, A., additional, Garcia, C., additional, Hernandez, J., additional, Perez-Saez, M. J., additional, Mir, M., additional, Anna, F., additional, Crespo, M., additional, Carta, P., additional, Zanazzi, M., additional, Antognoli, G., additional, Di Maria, L., additional, Caroti, L., additional, Ray, D. S., additional, Mukherjee, K., additional, Bohidar, N. P., additional, Pattanaik, A., additional, Das, P., additional, Thukral, S., additional, Kimura, T., additional, Yagisawa, T., additional, Ishikawa, N., additional, Sakuma, Y., additional, Fujiwara, T., additional, Nukui, A., additional, Gavela, E. E., additional, Sancho, A. A., additional, Kanter, J. J., additional, Avila, A. A., additional, Beltran, S. S., additional, Pallardo, L. L., additional, Dawoud, F. G., additional, Aithal, V., additional, Majernikova, M., additional, Rosenberger, J., additional, Prihodova, L., additional, Nagyova, I., additional, Jarcuskova, M., additional, Roland, R., additional, Groothoff, J. W., additional, van Dijk, J. P., additional, van Agteren, M., additional, de Weerd, A., additional, van de Wetering, J., additional, IJzermans, J., additional, Betjes, M., additional, Weimar, W., additional, Popoola, J., additional, Reed, A., additional, Tavarro, R., additional, Chryssanthopoulou, C., additional, MacPhee, I., additional, Mayor, M., additional, Franco, S., additional, Jara, P., additional, Ayala, R., additional, Orue, M. G., additional, Martinez, A., additional, Martinez, M., additional, Wasmouth, N., additional, Arik, G., additional, Yasar, A., additional, Yilmaz, S., additional, Arici, M., additional, Bihari Bansal, S., additional, Pokhariyal, S., additional, Jain, S., additional, Sethi, S., additional, Ahlawat, R., additional, Kher, V., additional, Martins, L. S., additional, Aguiar, P., additional, Dias, L., additional, Fonseca, I., additional, Henriques, A. C., additional, Cabrita, A., additional, Davide, J., additional, Sparkes, T. M., additional, Trofe-Clark, J., additional, Reese, P. P., additional, Jakobowski, D., additional, Goral, S., additional, Doll, S. L., additional, Abt, P. L., additional, Sawinski, D., additional, MBloom, R. D., additional, Knap, B., additional, Lukac, J., additional, Lukin, M., additional, Majcen, I., additional, Pavlovec, F., additional, Kandus, A., additional, Bren, A. F., additional, Kong, J. M., additional, Jeong, J. H., additional, Ahn, J., additional, Lee, D. R., additional, Son, S. H., additional, Kim, B. C., additional, Choi, W. Y., additional, Whang, E. J., additional, Czajka, B., additional, Malgorzewicz, S., additional, Panizo, N., additional, Rengel, M. A., additional, Vega, A., additional, Abad, S., additional, Tana, L., additional, Arroyo, D., additional, Rodriguez-Ferrero, M., additional, Perez de Jose, A., additional, Lopez-Gomez, J. M., additional, Koutroutsos, K., additional, Sackey, J., additional, Paolini, L., additional, Ramkhelawon, R., additional, Chowrimootoo, M., additional, Whelan, D., additional, Slatinska, J., additional, Honsova, E., additional, Wohlfahrtova, M., additional, Slimackova, E., additional, Rajnochova, S. B., additional, Viklicky, O., additional, Yankovoy, A., additional, Smith, I. S. J., additional, Wylie, E., additional, Ruiz-Esteban, P., additional, Lopez, V., additional, Garcia-Frias, P., additional, Cabello, M., additional, Gonzalez-Molina, M., additional, Vozmediano, C., additional, Hernandez, D., additional, Pavlovic, J., additional, Radivojevic, D., additional, Lezaic, V., additional, Simic-Ogrizovic, S., additional, Lausevic, M., additional, Naumovic, R., additional, Sakhuja, V., additional, Gundlapalli, S., additional, Rathi, M., additional, Jha, V., additional, Kohli, H. S., additional, Sharma, A., additional, Minz, M., additional, Nimgirova, A., additional, Esayan, A., additional, Kayukov, I., additional, Zuyeva, E., additional, Bilen, Y., additional, Cankaya, E., additional, Keles, M., additional, Gulcan, E., additional, Turkeli, M., additional, Albayrak, B., additional, Uyanik, A., additional, Yildirim, R., additional, Molitor, N., additional, Praktiknjo, M., additional, Abeygunaratne, T. N., additional, Balasubramanian, S., additional, Baker, R., additional, Nicholson, T., additional, Toprak, O., additional, Sari, Y., additional, Keceli, S., additional, Kurt, H., additional, Rocha, A., additional, Malheiro, J., additional, Pedroso, S., additional, Henriques, A., additional, Nihei, C., additional, Bacelar Marques, I., additional, Seguro, C. A., additional, Mate, G., additional, Martin, N., additional, Colon, L., additional, Casellas, L., additional, Garangou, D., additional, de la Torre, M., additional, Torguet, P., additional, Garcia, I., additional, Calabia, J., additional, Valles, M., additional, Pruthi, R., additional, Calestani, M., additional, Leydon, G., additional, Ravanan, R., additional, Roderick, P., additional, Korkmaz, S., additional, and Gulten, S., additional
- Published
- 2013
- Full Text
- View/download PDF
24. Kidney Transplant Recipients with Functioning Grafts for More than 15 Years
- Author
-
Celtik, A., primary, Alpay, N., additional, Celik, A., additional, Sezer, T.O., additional, Turkmen, A., additional, Camsari, T., additional, Toz, H., additional, Sever, M.S., additional, and Hoscoskun, C., additional
- Published
- 2013
- Full Text
- View/download PDF
25. Long-Term Prognostic Value of Coronary Flow Velocity Reserve in Renal Transplant Recipients
- Author
-
Akagun, T., primary, Caliskan, Y., additional, Alpay, N., additional, Ozkok, A., additional, Yazici, H., additional, Polat, N., additional, Guz, G., additional, Oflaz, H., additional, Turkmen, A., additional, and Sukru Sever, M., additional
- Published
- 2011
- Full Text
- View/download PDF
26. Investigation of schizophrenic patients from Istanbul, Turkey for the presence of West Nile virus
- Author
-
Aslan, M., primary, Kocazeybek, B., additional, Turan, N., additional, Karakose, A. R., additional, Altan, E., additional, Yuksel, P., additional, Saribas, S., additional, Cakan, H., additional, Caliskan, R., additional, Torun, M. M., additional, Balcioglu, I., additional, Alpay, N., additional, and Yilmaz, H., additional
- Published
- 2011
- Full Text
- View/download PDF
27. INTERRELATIONSHIP BETWEEN NONINVASIVE PREDICTORS OF ATHEROSCLEROSIS IN RENAL TRANSPLANTATION
- Author
-
Caliskan, Y., primary, Alpay, N., additional, Toz, B., additional, Akagun, T., additional, Kara, E., additional, Polat, N., additional, Guz, G., additional, Oflaz, H., additional, Turkmen, A., additional, Bozfakioglu, S., additional, and Sever, M. S., additional
- Published
- 2010
- Full Text
- View/download PDF
28. LONG-TERM PROGNOSTIC VALUE OF CORONARY FLOW VELOCITY RESERVE IN RENAL TRANSPLANT RECIPIENTS
- Author
-
Caliskan, Y., primary, Alpay, N., additional, Akagun, T., additional, Toz, B., additional, Kara, E., additional, Tufan, F., additional, Guz, G., additional, Polat, N., additional, Oflaz, H., additional, Turkmen, A., additional, and Sever, M. S., additional
- Published
- 2010
- Full Text
- View/download PDF
29. Assessment of Adrenal Functions in Patients with Autosomal Dominant Polycystic Kidney Disease
- Author
-
Tufan, F., primary, Uslu, B., additional, Cekrezi, B., additional, Uysal, M., additional, Alpay, N., additional, Turkmen, K., additional, Disci, R., additional, Ozbey, N., additional, and Ecder, T., additional
- Published
- 2010
- Full Text
- View/download PDF
30. Severe acetaminophen poisoning treated with a fractionated plasma separation and absorption system: A case report
- Author
-
Sebe, Ahmet, primary, Satar, Salim, additional, Rana Alpay, N., additional, Murt, Mesude, additional, and Güvenç, Birol, additional
- Published
- 2009
- Full Text
- View/download PDF
31. Establishing the Role of Latent Toxoplasmosis in the Ethiopathogenesis of Schizophrenia
- Author
-
Yuksel, P., primary, Kocazeybek, B., additional, Alpay, N., additional, Babur, C., additional, Bayar, R., additional, Karaköse, A.R., additional, Aksoy, C., additional, Aslan, M., additional, Mehmetali, S., additional, Kilic, S., additional, Balcioglu, I., additional, Hamanca, O., additional, Kucukbasmaci, O., additional, Oner, Y.A., additional, and Dirican, A., additional
- Published
- 2008
- Full Text
- View/download PDF
32. Unusual presentations of scorpion envenomation
- Author
-
Ranu Alpay, N, primary, Satar, S, additional, Sebe, A, additional, Demir, M, additional, and Topal, M, additional
- Published
- 2008
- Full Text
- View/download PDF
33. Leukocytoclastic Vasculitis due to Thalidomide in Multiple Myeloma
- Author
-
Yildirim, N. D., primary, Ayer, M., additional, Kucukkaya, R. D., additional, Alpay, N., additional, Mete, O., additional, Yenerel, M. N., additional, Yavuz, A. S., additional, and Nalcaci, M., additional
- Published
- 2007
- Full Text
- View/download PDF
34. Retroperitoneal Fibrosis Secondary to Different Etiologies (Hemilaminectomy and Hypothyroidism): Reports of Two Cases
- Author
-
Dişel, Umut, primary, Alpay, N. Rana, additional, and Paydas, Saime, additional
- Published
- 2007
- Full Text
- View/download PDF
35. The effect of propofol as an antioxidant agent in intravenous regional anesthesia
- Author
-
Erhan, O.L., primary, Bestas, A., additional, Gursu, F., additional, Alpay, N., additional, Ozer, A.B., additional, and Gulcu, F., additional
- Published
- 2006
- Full Text
- View/download PDF
36. Lymphoma and pulmonary involvement in primary Sjogren's syndrome: a case report.
- Author
-
Alpay N, Okumus G, Kiyan E, Kamali S, Dogan O, Yilmazbayhan D, Tabak L, and Arseven O
- Abstract
Here, we report a case of nodal marginal zone lymphoma in primary Sjögren's syndrome (SS) presenting with findings of pulmonary involvement. A 46-year-old woman was admitted to our hospital with fatigue, cough, dyspnea, xerostomia and weight loss. On physical examinations cervical and supraclavicular lymphadenopathies were noted. Chest X-P and computed tomographic films demonstrated reticular shadows in the bilateral lower lung and transbronchial lung biopsy revealed desquamative interstitial pneumonitis (DIP). Although immunoserological tests were negative, this patient was diagnosed as primary SS by sicca symptoms, positive Schirmer tear test and labial gland biopsy. Excisional biopsy of cervical lymph node revealed the presence of nodal marginal zone lymphoma. [ABSTRACT FROM AUTHOR]
- Published
- 2009
37. Unusual presentations of scorpion envenomation.
- Author
-
Alpay, N. Ranu, Satar, S., Sebe, A., Demir, M., and Topal, M.
- Subjects
- *
ARTHROPODA , *INVERTEBRATES , *PAUROPODA , *POISONOUS animals , *SCORPIONS , *ARACHNIDA - Abstract
Scorpions are nocturnal arthropods that inject their venom through the victims' skin by stingers. By the envenomation, clinical manifestations in a wide spectrum may occur, including pain at one side and death because of severe cardiopulmonary or neurological abnormalities. Sometimes the victim cannot describe the insect or does not remember even being stung after the event. We present two cases of scorpion envenomation with different and rare clinical situations with a short review of the literature. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
38. A case of heparin induced thrombocytopenia treated with fondaparinux.
- Author
-
Alpay N, Okumus G, Kiyan E, Diz-Küçükkaya R, Tabak L, Ece T, and Arseven O
- Abstract
Heparin induced thrombocytopenia (HIT) is an important complication of heparin treatment. In this article, we presented a case of HIT who was treated with fondaparinux, which is the only alternative anticoagulant agent in our country. A 48 year-old male patient was referred to our clinic when bilateral main pulmonary arterial thromboses were detected by spiral computerized tomography after he sought consultation for chest pain, dyspnea and presyncope of 3 days duration. In the physical examination, tachypnea, tachycardia, cyanosis, hypotension, neck vein distention, hepatomegaly and hepatojugular reflux were recorded. After the diagnosis of massive PTE, unfractionated heparin (UFH) infusion was started following the treatment with r-tPA. UFH was stopped due to the rapid fall in thrombocyte count (39000/mm[3]) on the second. day of treatment. PF4-heparin antibodies detected by ELISA were positive. Anticogulant therapy was followed with fondaparinux. Oral anticoagulant therapy was started when the thrombocyt count reached >100000/mm[3] on the sixth day of treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2009
39. Quetiapine administration for the management of psychosis in Juvenile Parkinson's disease: a case report.
- Author
-
Sezgin E, Tomruk NB, and Alpay N
- Abstract
Copyright of Archives of Neuropsychiatry / Nöropsikiyatri Arşivi is the property of Turkish Association of Neuropsychiatry and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2009
40. Introducing the non-B DNA Motif Search Tool (nBMST)
- Author
-
Albino Bacolla, Ming Yi, Regina Z. Cer, Robert M. Stephens, Duncan E. Donohue, Uma Mudunuri, Jack R. Collins, Alpay N Temiz, Natalia Volfovsky, Brian T. Luke, and Kevin H. Bruce
- Subjects
0106 biological sciences ,Genetics ,0303 health sciences ,Inverted repeat ,FASTA format ,Registered user ,Genome browser ,Computational biology ,Biology ,010603 evolutionary biology ,01 natural sciences ,Genome ,DNA sequencing ,3. Good health ,03 medical and health sciences ,chemistry.chemical_compound ,chemistry ,Poster Presentation ,Direct repeat ,DNA ,030304 developmental biology - Abstract
DNA sequence motifs with the ability to form non-B (non-canonical) structures have been linked to a variety of regulatory and pathological processes. Although the exact mechanism is unknown, recent work has provided significant evidence that non-B DNA structures may play a role in DNA instability and mutagenesis, leading to both DNA rearrangements and increased mutational rates, which are hallmarks of cancer. We have developed algorithms to identify a wide variety of non-B-DNA-forming motifs, including G-quadruplex-forming repeats, direct repeats and slipped motifs, inverted repeats and cruciform motifs, mirror repeats and triplex motifs, and A-phased repeats. After identifying these motifs in the mammalian reference genomes of human, mouse, chimpanzee, macaque, cow, dog, rat and platypus, the data were made publicly available in non-B DB [1]. However, it soon became apparent that it was not feasible to annotate the ever-growing list of genomic data and that it would be more effective to provide researchers with a systematic tool to predict these motifs in their own genomic data. Thus, the non-B DNA Motif Search Tool (nBMST) was created, and it is freely available online [2]. nBMST is a web interface that enables researchers to interactively submit any DNA sequence for searching for non-B DNA motifs. Once a user submits one or more DNA sequences in FASTA format, nBMST returns a comprehensive results page that contains the following: downloadable files in both a tab-delimited format and a generic feature format (GFF); a visualization, including PNG images; and a dynamic genome browser created using the Generic Genome Browser (GBrowse) [3] (version 2.0). Currently, nBMST allows file sizes of up to 20 MB of DNA sequence to be uploaded and stores the results for registered users for up to six months. In summary, the purpose of nBMST is to help provide insight into the involvement of alternative DNA conformations in cancer and other diseases, as well as into other potential biological functions.
- Full Text
- View/download PDF
41. Rare neurological syndromes associated with systemic lupus erythematosus.
- Author
-
Durmus H, Tüzün E, Alpay N, Icöz S, Kürtüncü M, and Demir GA
- Abstract
Copyright of Archives of Neuropsychiatry / Nöropsikiyatri Arşivi is the property of Turkish Association of Neuropsychiatry and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2010
42. Effects of propofol, ketamine-propofol mixture in pediatric dental patients undergoing intravenous sedation: a clinical study.
- Author
-
Isık G, Alpay N, Daglioglu G, and Ciftci V
- Subjects
- Humans, Child, Female, Male, Child, Preschool, Prospective Studies, Hypnotics and Sedatives administration & dosage, Hypnotics and Sedatives adverse effects, Conscious Sedation methods, Anesthesia Recovery Period, Anxiety, Ketamine administration & dosage, Ketamine adverse effects, Propofol administration & dosage, Propofol adverse effects
- Abstract
This study aimed to evaluate the clinical effects, complications (peri- and postoperative), depth of sedation, recovery times, and changes in anxiety levels in paediatric dental patients receiving intravenous sedation with propofol and ketamine-propofol mixtures. This prospective clinical study included 69 healthy children (ASA 1) aged 3-7 years. The patients were assigned randomly to propofol group (n = 23), which received propofol; 1:3 ketofol group (n = 23), which received 1:3 ketofol; or 1:4 ketofol group (n = 23), which received 1:4 ketofol. The bispectral index (BIS) and Ramsay Sedation Scale (RSS) score were recorded at intervals of 5 min to measure the depth of sedation, and vital signs were evaluated. Peri- and postoperative complications and recovery times were recorded. Anxiety levels were also evaluated using the Facial Image Scale (FIS) and changes in saliva cortisol levels (SCLs) before and after the intravenous sedation procedure. The Kruskal‒Wallis test and Wilcoxon signed-rank test were used to determine pre- and posttreatment parameters. Dunn's test for post hoc analysis was used to determine the differences among groups. Children's pre- and posttreatment anxiety levels did not differ significantly according to FIS scores, and increases in SCLs were detected in 1:3 ketofol and 1:4 ketofol groups after dental treatment was completed. Compared with those in the other groups, the BIS values of the patients in 1:4 ketofol indicated a slightly lower depth of sedation. The recovery time of the patients in 1:3 ketofol was longer than that of patients in propofol and 1:4 ketofol. The incidence of postoperative complications (agitation, hypersalivation, nausea/vomiting, and diplopia) did not differ among the groups. Ketamine-propofol combinations provided effective sedation similar to that of propofol infusion without any serious complications during dental treatment performed under intravenous sedation. The ketofol infusion increased the anxiety level of paediatric dental patients to a greater extent than the propofol infusion., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
43. The effect of mindfulness meditation on dental anxiety during implant surgery: a randomized controlled clinical trial.
- Author
-
Turer OU, Ozcan M, Alkaya B, Demirbilek F, Alpay N, Daglioglu G, Seydaoglu G, and Haytac MC
- Subjects
- Humans, Dental Anxiety, Anxiety therapy, Anxiety psychology, Anxiety Disorders, Meditation, Mindfulness, Dental Implants
- Abstract
Dental implant surgery is almost always associated with patient anxiety. Anxiety during dental surgical procedures triggers an increase in sympathetic activity. Mindfulness meditation (MM) is often associated with high levels of relaxation in the form of increased parasympathetic tone and decreased sympathetic activity. However, the effect of MM on dental anxiety is not clear. The current study aimed to show the effects of a MM as a sedative technique during dental implant surgery by examining the State-Trait Anxiety Inventory (STAI-S), bispectral index (BIS), cortisol levels (CL), systolic (SBP) and diastolic blood pressure (DBP), heart rate (HR) and saturation (SpO
2 ) parameters. HR, SBP, DBP, SpO2 , BIS score and CLs were compared at the baseline, immediately before-, during-, and immediately after surgery between the test and control groups. We found that the MM resulted in significant decrease in BIS together with positive effects on hemodynamic parameters (decrease of HR, SBP, DBP and increase of SpO2 ), psychological findings (improvement on STAI-S scores) and biochemical outcomes (decreased CL). In conclusion, the results demonstrate that MM appeared to be a reliable strategy for managing stress during dental implant operation with benefits in psychological, physiological and biochemical outcomes., (© 2023. The Author(s).)- Published
- 2023
- Full Text
- View/download PDF
44. Effects of Cinacalcet on Post-transplantation Hypercalcemia and Hyperparathyroidism in Adult Kidney Transplant Patients: A Single-Center Experience.
- Author
-
Alpay N and Yıldız A
- Abstract
Objective: Secondary hyperparathyroidism may manifest as hypercalcemia in the post-transplant period. The classical treatment method is parathyroidectomy and the alternative is oral cinacalcet, a calcimimetic agent therapy. We retrospectively investigated the effect of cinacalcet therapy on kidney and patient survival in these patients., Materials and Methods: In our single-center, retrospective, observational study, files of 934 patients who underwent renal transplantation in our unit between 2008 and 2022 were reviewed. A total of 23 patients were started on cinacalcet for the treatment of hypercalcemia (calcium > 10.3 mg/dl) and parathyroid hormone (PTH) elevation (>65 pg/ml). Patients with calcium < 10.3 mg/dl and PTH > 700 pg/ml at any time in the follow-up after renal transplantation were included in the study. In addition, the demographic data of the patients, baseline creatine, calcium, phosphorus, and PTH levels at the time of hypercalcemia, parathyroid ultrasonography, parathyroid scintigraphy, creatinine, calcium, phosphorus, and PTH levels in the last controls, and survival status were evaluated., Results: The mean age of 23 patients included in the study was 52.7 ± 11 years (minimum: 32; maximum: 66). Of the patients, 16 (69.6%) were male, and 15 (65.2%) were transplanted from a living donor. Parathyroid scintigraphic revealed adenoma in three (13%) patients, hyperplasia in five patients (21.7%), and no involvement in 15 patients (65.2%). Cinacalcet treatment was initiated at a median of 33 months (interquartile range (IQR) = 13-96) after the kidney transplant operation. There was no graft loss in the patients during the follow-up period. Twenty-two patients (95.7%) were alive, and one patient died. The calcium level of the patients decreased from 11.3 ± 0.64 mg/dl to 9.98 ± 0.78 mg/dl (p = 0.001) after cinacalcet treatment. Phosphorus values increased from 2.7 ± 0.65 mg/dl to 3.10 ± 0.65 mg/dl (p = 0.004). On the other hand, there was no significant difference in PTH levels between the initial and final controls (285 (IQR = 150-573) vs. 260 pg/ml (IQR = 175-411), p = 0.650). Also, creatinine levels were similar (1.2 ± 0.38 vs. 1.24 ± 0.48 mg/dl, p = 0.43). Despite cinacalcet treatment, calcium levels did not decrease in eight patients. Complications such as renal dysfunction and pathological fracture did not develop in these patients., Conclusions: It seems that cinacalcet treatment is a suitable option for patients with hypercalcemia and/or hyperparathyroidism with low drug interactions and good biochemical control after renal transplantation., Competing Interests: The authors have declared that no competing interests exist., (Copyright © 2023, Alpay et al.)
- Published
- 2023
- Full Text
- View/download PDF
45. Role of Sedation and Analgesia during Noninvasive Ventilation: Systematic Review of Recent Evidence and Recommendations.
- Author
-
Karim HM, Šarc I, Calandra C, Spadaro S, Mina B, Ciobanu LD, Gonçalves G, Caldeira V, Cabrita B, Perren A, Fiorentino G, Utku T, Piervincenzi E, El-Khatib M, Alpay N, Ferrari R, Abdelrahim ME, Saeed H, Madney YM, Harb HS, Vargas N, Demirkiran H, Bhakta P, Papadakos P, Gómez-Ríos MÁ, Abad A, Alqahtani JS, Hadda V, Singha SK, and Esquinas AM
- Abstract
Aim: This systematic review aimed to investigate the drugs used and their potential effect on noninvasive ventilation (NIV)., Background: NIV is used increasingly in acute respiratory failure (ARF). Sedation and analgesia are potentially beneficial in NIV, but they can have a deleterious impact. Proper guidelines to specifically address this issue and the recommendations for or against it are scarce in the literature. In the most recent guidelines published in 2017 by the European Respiratory Society/American Thoracic Society (ERS/ATS) relating to NIV use in patients having ARF, the well-defined recommendation on the selective use of sedation and analgesia is missing. Nevertheless, some national guidelines suggested using sedation for agitation., Methods: Electronic databases (PubMed/Medline, Google Scholar, and Cochrane library) from January 1999 to December 2019 were searched systematically for research articles related to sedation and analgosedation in NIV. A brief review of the existing literature related to sedation and analgesia was also done., Review Results: Sixteen articles (five randomized trials) were analyzed. Other trials, guidelines, and reviews published over the last two decades were also discussed. The present review analysis suggests dexmedetomidine as the emerging sedative agent of choice based on the most recent trials because of better efficacy with an improved and predictable cardiorespiratory profile., Conclusion: Current evidence suggests that sedation has a potentially beneficial role in patients at risk of NIV failure due to interface intolerance, anxiety, and pain. However, more randomized controlled trials are needed to comment on this issue and formulate strong evidence-based recommendations., How to Cite This Article: Karim HMR, Šarc I, Calandra C, Spadaro S, Mina B, Ciobanu LD, et al. Role of Sedation and Analgesia during Noninvasive Ventilation: Systematic Review of Recent Evidence and Recommendations. Indian J Crit Care Med 2022;26(8):938-948., Competing Interests: Source of support: Nil Conflict of interest: None, (Copyright © 2022; Jaypee Brothers Medical Publishers (P) Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
46. Immunological parameters associated with the severity of COVID-19 pneumonia in kidney transplant recipients.
- Author
-
Ozkok A, Alpay N, Alan S, Bakan ND, Soysal F, Yazici H, Ekşioğlu-Demiralp E, and Yildiz A
- Subjects
- Adult, Humans, Lymphocyte Count, Lymphocyte Subsets, Middle Aged, Pilot Projects, Transplant Recipients, COVID-19, Kidney Transplantation adverse effects
- Abstract
Purpose: An outbreak of a novel respiratory disease due to coronavirus species was emerged in 2019 and named as Coronavirus Disease-2019 (COVID-19). Clinical and immunological factors affecting the course of COVID-19 in kidney transplant recipients (KTR) are not well-known., Methods: In this prospective observational study, we presented 20 KTR with COVID-19 pnemonia and examined the factors predicting the severity of COVID-19. A total of 10 KTR without COVID-19 was used as control group. Lymphocyte subsets were determined by flow cytometry. In 13/20 patients, immunophenotyping was repeated 1 week later., Results: Mean age of the patients was 50 ± 9 years. Patients were classified as mild-moderate (oxygen saturation: SO
2 > 90%) and severe disease groups (SO2 ≤ 90%). Serum albumin and hemoglobin were lower and CRP, fibrinogen and peak D-dimer were higher in severe group. Peak CRP was inversely associated with nadir SO2 (r = - 0.68, p = 0.001). Neutrophil/lymphocyte ratio was higher in severe group (p = 0.01). CD3 + and CD4 + cells were lower and NK cell percentage (CD16 + 56 +) was higher in severe group. Percentage of spontaneously activated CD8 cells (CD8 + CD69 +) was higher in severe group. In comparison of KTR with and without COVID-19, CD8 + cells were lower but NK cell percentage was higher in KTR with COVID-19., Conclusion: In this pilot study, increased NK cells, activated CD8 + cells and decreased CD3 + and CD4 + cells were associated with severity of COVID-19 in KTR. Peripheral immunophenotyping of lymphocyte subtypes may provide prognostic information about the clinical course of COVID-19 in KTR., (© 2021. The Author(s), under exclusive licence to Springer Nature B.V.)- Published
- 2022
- Full Text
- View/download PDF
47. Peripheral innate and adaptive immune cells during COVID-19: Functional neutrophils, pro-inflammatory monocytes, and half-dead lymphocytes.
- Author
-
Ekşioğlu-Demiralp E, Alan S, Sili U, Bakan D, Ocak İ, Yürekli R, Alpay N, Görçin S, and Yıldız A
- Subjects
- CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Flow Cytometry, Humans, Neutrophils, SARS-CoV-2, COVID-19, Monocytes
- Abstract
Background: A better understanding of innate and adaptive cells in COVID-19 is necessary for the development of effective treatment methods and vaccines., Methods: We studied phenotypic features of innate and adaptive immune cells, oxidative burst, phagocytosis, and apoptosis. One hundred and three patients with COVID-19 were grouped according to their clinical features into the categories of mild (35%), moderate (40.8%), and severe (24.3%)., Results: Monocytes were CD16
+ pro-inflammatory monocytes and tended to shed their HLA-DR, especially in severe cases (p < 0.01). Neutrophils were mature and functional, although a decline of their CD10 and CD16 was observed (p < 0.01). No defect was found in the reactive oxygen species production and their apoptosis. The percentage of natural killer cells was in the normal range, whereas the percentages of CD8+ NK and CD56+ T lymphocytes were found to be high (p < 0.01). Although the absolute numbers of all lymphocyte subsets were low and showed a tendency for a gradual decrease in accordance with the disease progression, the most decreased absolute number was that of B lymphocytes, followed by CD4+ T cells in the severe cases. The percentages of double-negative T cells; HLA-DR+ CD3+ and CD28- CD8+ subsets were found to be significantly increased. Importantly, we demonstrated the increased baseline activation of caspase-3 and increased lymphocyte apoptosis., Conclusion: We suggest that SARS-CoV-2 primarily affects the lymphocytes and not the innate cells. The increased baseline activation of Caspase-3 could make the COVID-19 lymphocytes more vulnerable to cell death. Therefore, this may interrupt the crosstalk between the adaptive and innate immune systems., (© 2021 International Clinical Cytometry Society.)- Published
- 2022
- Full Text
- View/download PDF
48. High-Flow Nasal Oxygen Therapy in Acute Hypoxemic Respiratory Failure: Concise Review on Technology and Initial Methodology.
- Author
-
Guia M, Alpay N, Gerardo A, Madney Y, Abdelrahim M, Saeed H, Harb H, Gonçalves G, Cabrita B, Alqahtani J, El-Khatib M, Gómez-Ríos M, Fakharian A, Ciobanu L, Karim HMR, Piervincenzi E, Scharffenberg M, Steiropoulos P, LeMaster W, Barjaktarevic I, Wittenstein J, Diaz-Abad M, Perren A, Nicolini A, Spadaro S, Garuti G, Petroianni A, and Esquinas A
- Abstract
High-flow nasal cannula oxygen therapy (HFNCOT) system consists of an air/oxygen supply system capable of delivering up to 100% humidified and heated oxygen at a flow rate of up to 80 L/min. The system includes a blender, active humidifier, single heated tube, and nasal cannula. HFNCOT has many physiological advantages compared with other standard oxygen therapies, such as anatomical dead space washout, more constant fraction of inspired oxygen, positive end-expiratory (PEEP) effect, supplement of adequate humidification and maintenance of muco-ciliary function. HFNCOT is mostly used for hypoxemic acute respiratory failure, although it also has other indications. HFNCOT is a common choice of physicians as its technology makes it more silent and comfortable. Though HFNCOT is used in many clinical settings, there is a lack of publications addressing devices and initial settings. We present a review on HFNCOT, with focus on device and application methodology.
- Published
- 2021
- Full Text
- View/download PDF
49. Predicting the outcome of COVID-19 infection in kidney transplant recipients.
- Author
-
Oto OA, Ozturk S, Turgutalp K, Arici M, Alpay N, Merhametsiz O, Sipahi S, Ogutmen MB, Yelken B, Altiparmak MR, Gorgulu N, Tatar E, Ozkan O, Ayar Y, Aydin Z, Dheir H, Ozkok A, Safak S, Demir ME, Odabas AR, Tokgoz B, Tonbul HZ, Sezer S, Ates K, and Yildiz A
- Subjects
- Acute Kidney Injury etiology, Acute Kidney Injury therapy, Adult, Age Factors, COVID-19 blood, COVID-19 mortality, Creatinine blood, Critical Care, Female, Graft Survival physiology, Hospital Mortality, Humans, Length of Stay, Lymphocyte Count, Male, Middle Aged, Myocardial Ischemia complications, Renal Replacement Therapy, Respiration, Artificial, Retrospective Studies, Risk Factors, SARS-CoV-2, Serum Albumin metabolism, Transplant Recipients, Treatment Outcome, Turkey epidemiology, COVID-19 complications, COVID-19 therapy, Kidney Transplantation
- Abstract
Background: We aimed to present the demographic characteristics, clinical presentation, and outcomes of our multicenter cohort of adult KTx recipients with COVID-19., Methods: We conducted a multicenter, retrospective study using data of patients hospitalized for COVID-19 collected from 34 centers in Turkey. Demographic characteristics, clinical findings, laboratory parameters (hemogram, CRP, AST, ALT, LDH, and ferritin) at admission and follow-up, and treatment strategies were reviewed. Predictors of poor clinical outcomes were analyzed. The primary outcomes were in-hospital mortality and the need for ICU admission. The secondary outcome was composite in-hospital mortality and/or ICU admission., Results: One hundred nine patients (male/female: 63/46, mean age: 48.4 ± 12.4 years) were included in the study. Acute kidney injury (AKI) developed in 46 (42.2%) patients, and 4 (3.7%) of the patients required renal replacement therapy (RRT). A total of 22 (20.2%) patients were admitted in the ICU, and 19 (17.4%) patients required invasive mechanical ventilation. 14 (12.8%) of the patients died. Patients who were admitted in the ICU were significantly older (age over 60 years) (38.1% vs 14.9%, p = 0.016). 23 (21.1%) patients reached to composite outcome and these patients were significantly older (age over 60 years) (39.1% vs. 13.9%; p = 0.004), and had lower serum albumin (3.4 g/dl [2.9-3.8] vs. 3.8 g/dl [3.5-4.1], p = 0.002), higher serum ferritin (679 μg/L [184-2260] vs. 331 μg/L [128-839], p = 0.048), and lower lymphocyte counts (700/μl [460-950] vs. 860 /μl [545-1385], p = 0.018). Multivariable analysis identified presence of ischemic heart disease and initial serum creatinine levels as independent risk factors for mortality, whereas age over 60 years and initial serum creatinine levels were independently associated with ICU admission. On analysis for predicting secondary outcome, age above 60 and initial lymphocyte count were found to be independent variables in multivariable analysis., Conclusion: Over the age of 60, ischemic heart disease, lymphopenia, poor graft function were independent risk factors for severe COVID-19 in this patient group. Whereas presence of ischemic heart disease and poor graft function were independently associated with mortality.
- Published
- 2021
- Full Text
- View/download PDF
50. Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey.
- Author
-
Ozturk S, Turgutalp K, Arici M, Odabas AR, Altiparmak MR, Aydin Z, Cebeci E, Basturk T, Soypacaci Z, Sahin G, Elif Ozler T, Kara E, Dheir H, Eren N, Suleymanlar G, Islam M, Ogutmen MB, Sengul E, Ayar Y, Dolarslan ME, Bakirdogen S, Safak S, Gungor O, Sahin I, Mentese IB, Merhametsiz O, Oguz EG, Genek DG, Alpay N, Aktas N, Duranay M, Alagoz S, Colak H, Adibelli Z, Pembegul I, Hur E, Azak A, Taymez DG, Tatar E, Kazancioglu R, Oruc A, Yuksel E, Onan E, Turkmen K, Hasbal NB, Gurel A, Yelken B, Sahutoglu T, Gok M, Seyahi N, Sevinc M, Ozkurt S, Sipahi S, Bek SG, Bora F, Demirelli B, Oto OA, Altunoren O, Tuglular SZ, Demir ME, Ayli MD, Huddam B, Tanrisev M, Bozaci I, Gursu M, Bakar B, Tokgoz B, Tonbul HZ, Yildiz A, Sezer S, and Ates K
- Subjects
- Adult, Aged, Comorbidity, Female, Hospital Mortality trends, Hospitalization trends, Humans, Male, Middle Aged, Renal Insufficiency, Chronic therapy, Retrospective Studies, Risk Factors, SARS-CoV-2, Time Factors, Turkey epidemiology, COVID-19 epidemiology, Kidney Transplantation, Renal Dialysis methods, Renal Insufficiency, Chronic epidemiology
- Abstract
Background: Chronic kidney disease (CKD) and immunosuppression, such as in renal transplantation (RT), stand as one of the established potential risk factors for severe coronavirus disease 2019 (COVID-19). Case morbidity and mortality rates for any type of infection have always been much higher in CKD, haemodialysis (HD) and RT patients than in the general population. A large study comparing COVID-19 outcome in moderate to advanced CKD (Stages 3-5), HD and RT patients with a control group of patients is still lacking., Methods: We conducted a multicentre, retrospective, observational study, involving hospitalized adult patients with COVID-19 from 47 centres in Turkey. Patients with CKD Stages 3-5, chronic HD and RT were compared with patients who had COVID-19 but no kidney disease. Demographics, comorbidities, medications, laboratory tests, COVID-19 treatments and outcome [in-hospital mortality and combined in-hospital outcome mortality or admission to the intensive care unit (ICU)] were compared., Results: A total of 1210 patients were included [median age, 61 (quartile 1-quartile 3 48-71) years, female 551 (45.5%)] composed of four groups: control (n = 450), HD (n = 390), RT (n = 81) and CKD (n = 289). The ICU admission rate was 266/1210 (22.0%). A total of 172/1210 (14.2%) patients died. The ICU admission and in-hospital mortality rates in the CKD group [114/289 (39.4%); 95% confidence interval (CI) 33.9-45.2; and 82/289 (28.4%); 95% CI 23.9-34.5)] were significantly higher than the other groups: HD = 99/390 (25.4%; 95% CI 21.3-29.9; P < 0.001) and 63/390 (16.2%; 95% CI 13.0-20.4; P < 0.001); RT = 17/81 (21.0%; 95% CI 13.2-30.8; P = 0.002) and 9/81 (11.1%; 95% CI 5.7-19.5; P = 0.001); and control = 36/450 (8.0%; 95% CI 5.8-10.8; P < 0.001) and 18/450 (4%; 95% CI 2.5-6.2; P < 0.001). Adjusted mortality and adjusted combined outcomes in CKD group and HD groups were significantly higher than the control group [hazard ratio (HR) (95% CI) CKD: 2.88 (1.52-5.44); P = 0.001; 2.44 (1.35-4.40); P = 0.003; HD: 2.32 (1.21-4.46); P = 0.011; 2.25 (1.23-4.12); P = 0.008), respectively], but these were not significantly different in the RT from in the control group [HR (95% CI) 1.89 (0.76-4.72); P = 0.169; 1.87 (0.81-4.28); P = 0.138, respectively]., Conclusions: Hospitalized COVID-19 patients with CKDs, including Stages 3-5 CKD, HD and RT, have significantly higher mortality than patients without kidney disease. Stages 3-5 CKD patients have an in-hospital mortality rate as much as HD patients, which may be in part because of similar age and comorbidity burden. We were unable to assess if RT patients were or were not at increased risk for in-hospital mortality because of the relatively small sample size of the RT patients in this study., (© The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.